학술논문
927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S667-S667
Subject
Language
ISSN
0923-7534